Filing Flows › Vivos Therapeutics (VVOS) › Q1 2025
Vivos Therapeutics (VVOS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Vivos Therapeutics (VVOS) reported revenue of $3.0M for the first quarter 2025 (Q1 2025), -12% from a year earlier and -18% from the quarter before. Operating margin was -129.9%, net loss $3.9M (128.1% of revenue).
Vivos Therapeutics, Q1 2025: revenue $3.0M (-12% year over year), operating margin -129.9%, net loss $3.9M, operating cash flow −$3.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | -18% | -12% |
| Operating profit | −$3.9M | — | — |
| Net earnings | −$3.9M | — | — |
| Operating cash flow | −$3.8M | — | — |
What changed
Revenue was $3.0M in Q1 2025, down 12% year over year and down 18% from the previous quarter. Appliances was the largest line at 42% of revenue. VIP lost $684K year over year (down 75%), 170% of the total change.
Gross margin was 50.0%, down 6.6 points from a year earlier. Operating costs exceeded revenue by $3.9M, an operating margin of -129.9%. Operating expenses fell 5% while revenue fell 12%. The fastest-growing cost line was Other operating costs (+285%). The quarter ended with a net loss of $3.9M, wider than the previous quarter's $2.8M loss.
Operating cash flow was −$3.8M. Non-cash charges added back $177K of depreciation and amortization and $317K of share-based compensation. Working capital and other items used $426K. Capital expenditures of $122K exceeded it, leaving free cash flow of −$3.9M.
Questions
What was Vivos Therapeutics' revenue in the first quarter 2025?
Vivos Therapeutics (VVOS) reported revenue of $3.0M for the first quarter 2025 (Q1 2025), -12% from a year earlier and -18% from the quarter before.
Was Vivos Therapeutics profitable in the first quarter 2025?
Operating loss was $3.9M (-129.9% of revenue) and net loss $3.9M.
Source: Vivos Therapeutics 10-Q on SEC EDGAR.